经中国证券监督管理委员会证监许可[2023]1531 号文《关于核准吉林省中研 高分子材料股份有限公司首次公开发行股票的批复》，公司向社会公开发行人民 币普通股（A 股）3,042 万股，募集资金总额 902,257,200.00 元。扣除尚未支付的 承销费和保荐费（不含税）68,866,635.48 元后的募集资金为人民币 833,390,564.52 元，减除其他发行费用（不含税）人民币 102,543,821.47 元后，实际募集资金净 额为人民币 799,713,378.53 元。上述募集资金到位情况经大华会计师事务所（特 殊普通合伙）验证，并出具了大华验字[2023]000548 号验资报告。 （二）募集资金以前年度使用金额 国泰海通证券股份有限公司 关于吉林省中研高分子材料股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 吉林省中研高分子材料股份有限公司（以下简称"中研股份"或"公司"）的持 续督导机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海 ...

吉林省中研高分子材料股份有限公司 内部控制审计报告 德皓内字[2025]00000024 号 Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 吉林省中研高分子材料股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 内部控制审计报告 德皓内字[2025]00000024 号 北京德皓国际会计师事务所 (特殊普通合伙 ) 吉林省中研高分子材料股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了吉林省中研高分子材料股份有限公司（以下简称 中研股份）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效 ...

吉林省中研高分子材料股份有限公司 2024 年度独立董事述职报告 本人苏志勇，现担任吉林省中研高分子材料股份有限公司（以下简称"公司"） 的独立董事，2024年度严格按照《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司独立董事管理办法》、《上海证券交易所科创板股票上市规则》等法律、法规、 规范性文件，及《吉林省中研高分子材料股份有限公司章程》（以下简称"《公 司章程》"）《吉林省中研高分子材料股份有限公司独立董事工作制度》（以下 简称"《独立董事工作制度》"）等规定和要求，谨慎、认真、诚实、勤勉、独 立的履行独立董事职责，积极参与公司重大决策，出席相关会议，认真审议董事 会各项议案，公正、客观、审慎地发表意见，维护公司和全体股东尤其是中小股 东的合法权益，充分发挥了独立董事、提名委员会的作用，现将本人2024年履行 独立董事职责的情况汇报如下： 一、独立董事的基本情况 或其他可能妨碍我进行独立客观判断的关系，不存在影响独立董事独立性的情况， 符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监管 指引第1号——规范运作》中对 ...

吉林省中研高分子材料股份有限公司 2024 年度独立董事述职报告 本人周佰成，现担任吉林省中研高分子材料股份有限公司（以下简称"公司"） 的独立董事，2024年度严格按照《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司独立董事管理办法》、《上海证券交易所科创板股票上市规则》等法律、法规、 规范性文件，及《吉林省中研高分子材料股份有限公司章程》（以下简称"《公 司章程》"）《吉林省中研高分子材料股份有限公司独立董事工作制度》（以下 简称"《独立董事工作制度》"）等规定和要求，谨慎、认真、诚实、勤勉、独 立的履行独立董事职责，积极参与公司重大决策，出席相关会议，认真审议董事 会各项议案，公正、客观、审慎地发表意见，维护公司和全体股东尤其是中小股 东的合法权益，充分发挥了独立董事、审计委员会、提名委员会、薪酬和考核委 员会及战略委员会的作用，现将本人2024年履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事个人工作履历、专业背景以及兼职情况 周佰成，1974年11月生，中国国籍，无境外永久居留权，毕业于吉林大学商 学院数量 ...

吉林省中研高分子材料股份有限公司 2024 年度独立董事述职报告 本人安亚人，现担任吉林省中研高分子材料股份有限公司（以下简称"公司"） 的独立董事，2024年度严格按照《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司独立董事管理办法》、《上海证券交易所科创板股票上市规则》等法律、法规、 规范性文件，及《吉林省中研高分子材料股份有限公司章程》（以下简称"《公 司章程》"）《吉林省中研高分子材料股份有限公司独立董事工作制度》（以下 简称"《独立董事工作制度》"）等规定和要求，谨慎、认真、诚实、勤勉、独 立的履行独立董事职责，积极参与公司重大决策，出席相关会议，认真审议董事 会各项议案，公正、客观、审慎地发表意见，维护公司和全体股东尤其是中小股 东的合法权益，充分发挥了独立董事、审计委员会及薪酬和考核委员会的作用， 现将本人2024年履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事个人工作履历、专业背景以及兼职情况 （一）出席董事会情况 2024年，公司共召开六次董事会会议。作为独立董事，我认真审阅相关议案， 积极参与讨 ...

Financial Performance - The company reported a revenue of CNY 277.09 million in 2024, a decrease of 5.05% compared to 2023[24]. - Net profit attributable to shareholders was CNY 39.28 million, down 27.99% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 24.53 million, a decline of 40.12%[25]. - Basic and diluted earnings per share decreased by 41.82% to CNY 0.32 in 2024[23]. - The weighted average return on equity fell to 3.34%, a decrease of 6.5 percentage points from the previous year[23]. - The company's comprehensive gross margin for the reporting period was 40.08%, an increase from 39.48% in the previous period, indicating strong market position and competitive strength[86]. - The company's inventory value at the end of the reporting period was 145.91 million yuan, accounting for 14.75% of current assets, highlighting the significant inventory levels related to the PEEK industry[86]. - Accounts receivable at the end of the reporting period amounted to 46.52 million yuan, with 93.86% of it due within one year, reflecting a healthy aging structure[87]. - The company's operating revenue for 2024 was CNY 277.09 million, a decrease of 5.05% year-on-year, primarily due to a voluntary price reduction on certain products[94]. - The operating cost decreased by 6.00% year-on-year to CNY 166.03 million, attributed to effective procurement strategies and production process improvements[95]. Dividend Policy - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares, totaling 24,336,000.00 RMB, which represents 61.95% of the net profit attributable to shareholders for the year[6]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2024 fiscal year[6]. - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profits to be allocated as cash dividends each year[198]. - The company has a policy to prioritize cash dividends unless significant investment plans arise, in which case the dividend ratio may be adjusted[198]. - The company mandates a minimum cash dividend ratio of 40% for mature-stage companies with significant capital expenditure plans[199]. - For growth-stage companies with significant capital expenditure plans, the minimum cash dividend ratio is set at 20%[199]. - The board must ensure that stock dividends align with the company's operational scale and profit growth rate[199]. Research and Development - The company achieved a total R&D investment of CNY 31,924,137.16, representing a 38.36% increase compared to the previous year[67]. - R&D expenses accounted for 11.52% of total revenue, an increase of 3.61 percentage points from the previous year[67]. - The company obtained 5 new patents during the reporting period, bringing the total number of patents to 34, including 25 invention patents[65]. - The company has developed two new grades of medical-grade PEEK resin products, ZR3G and ZR7G, to meet the growing demand in the medical sector[69]. - The company is actively pursuing technology upgrades and product innovation to maintain its competitive edge, leading to increased R&D investment[25]. - The company has been recognized as a national-level "Little Giant" enterprise for specialized and innovative manufacturing in 2024[64]. - The company is focusing on the development of advanced materials, including high-performance fibers and biodegradable materials, as part of the "14th Five-Year Plan" for industrial development[116]. Market Expansion and Strategy - The company is actively expanding its market presence in the semiconductor sector, focusing on high-performance plastic components for semiconductor manufacturing[55]. - The company has established partnerships with several medical technology firms to develop PEEK products for thoracic, orthopedic, and neurosurgical applications, enhancing its market position in the healthcare sector[56]. - The company aims to explore new application areas for PEEK materials and enhance market penetration across various industries[34]. - The company is set to launch its European overseas warehouse to enhance its brand influence and competitiveness in the global market[161]. - The company plans to enter two new international markets by Q3 2024, aiming for a 15% market share in those regions[171]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[171]. Operational Efficiency - The company has implemented an automated control system in its main production lines, enhancing production efficiency and stability of PEEK product batches[130]. - The company has optimized its production line and capacity structure, resulting in reduced consumption of main raw materials and refined energy consumption[130]. - The company has achieved significant improvements in heat transfer efficiency and reaction completeness through optimized reactor design[60]. - The company has implemented five major management tools for product quality control, including Statistical Process Control (SPC) and Failure Mode and Effects Analysis (FMEA)[61]. Risk Management - The company faces risks related to the loss of core technical personnel, which could adversely affect production and business development due to increased competition for talent[84]. - The company is exposed to risks from fluctuations in gross margin, which could decline if it fails to innovate or if market competition intensifies[86]. - The company relies heavily on a limited number of suppliers for key raw materials, specifically fluoroketone, which constitutes approximately 54% of the production cost for PEEK powder[89]. - The company has implemented internal control systems to manage the risks associated with its expanding business scale and operational complexity[85]. Corporate Governance - The company has maintained a stable management structure with no significant changes in senior management roles during the reporting period[178]. - The company held a total of 6 board meetings during the year, with no in-person meetings[183]. - The audit committee convened 8 times during the reporting period, approving all proposed resolutions[186]. - The company has established a remuneration and assessment committee to determine the compensation plans for directors and senior management[177]. - The company’s independent directors have consistently attended board meetings and shareholder meetings, ensuring governance compliance[181].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥64,564,876.11, representing a 64.81% increase compared to ¥39,175,794.17 in the same period last year[3] - Net profit attributable to shareholders was ¥5,660,174.75, a significant increase of 6,430.46% from ¥86,673.42 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥3,690,524.76, up 1,786.46% from ¥195,632.31 in the previous year[3] - Basic and diluted earnings per share were both ¥0.05, a substantial increase from ¥0.0007 in the previous year, reflecting a growth of 7,042.86%[3] - Operating profit for Q1 2025 was ¥6,094,467.19, recovering from a loss of ¥42,448.81 in Q1 2024[18] - Net profit for Q1 2025 was ¥5,660,174.75, compared to a net profit of ¥86,673.42 in Q1 2024, indicating a substantial improvement[18] Research and Development - The company's R&D investment totaled ¥8,683,182.91, which is a 40.52% increase from ¥6,179,394.71 in the same period last year[3] - Research and development expenses increased to ¥8,311,779.66 in Q1 2025, up from ¥6,797,409.08 in Q1 2024, reflecting a focus on innovation[17] - The proportion of R&D investment to operating revenue decreased by 3.85 percentage points to 13.45% from 15.77% year-on-year[3] - The company has a significant focus on PEEK (polyether ether ketone) as a high-performance engineering plastic for various applications[11] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of ¥15,053,275.83, worsening by 51.68% compared to a net outflow of ¥9,924,108.80 last year[3] - Cash and cash equivalents at the end of Q1 2025 were ¥475,977,928.33, down from ¥633,767,421.06 at the end of Q1 2024[21] - The company reported a cash balance of RMB 475,977,928.33 as of March 31, 2025, down from RMB 552,095,478.74 at the end of 2024[13] - Total assets at the end of the reporting period were ¥1,321,502,454.99, a decrease of 2.44% from ¥1,354,484,847.76 at the end of the previous year[4] - The company's current assets totaled RMB 930,751,606.54, down from RMB 988,891,466.09 at the end of 2024[14] - Total operating costs of ¥61,038,626.38 in Q1 2025, up from ¥39,590,455.27 in Q1 2024, reflecting increased operational expenses[17] Liabilities and Equity - The total liabilities decreased to RMB 143,688,303.38 from RMB 182,330,870.90 at the end of 2024[15] - The company's long-term borrowings remained stable at RMB 37,000,000.00 as of March 31, 2025[15] - Total assets and equity amounted to ¥1,321,502,454.99 and ¥1,177,814,151.61 respectively, indicating a stable financial position[16] Government Subsidies and Shareholding - The company reported a government subsidy of ¥273,971.01, which is expected to have a continuous impact on its profits[6] - The company plans to reduce shareholding by 1,216,800 shares, not exceeding 1% of the total share capital[12] Sales Performance - The company reported a significant increase in sales revenue, with cash received from sales reaching ¥32,860,007.33 in Q1 2025, compared to ¥25,135,654.35 in Q1 2024[20] - The company's revenue increased by 64.81% year-on-year, primarily due to an increase in product sales[12]

吉林省中研高分子材料股份有限公司 2024 年度财务决算报告 吉林省中研高分子材料股份有限公司（以下简称"公司"）2024 年 12 月 31 日财务报表已经北京德皓国际会计师事务所（特殊普通合伙）审计，并出具德皓 审字[2025]00000633 号标准无保留意见的《审计报告》。现将财务决算情况汇报 如下： 一、主要会计数据和财务指标 （一）主要会计数据 单位：人民币元 | 主要会计数据 | 2024 年 | 2023 年 | 本期比上年同 | | --- | --- | --- | --- | | | | | 期增减(%) | | 营业收入 | 277,091,212.17 | 291,837,050.28 | -5.05 | | 归属于上市公司股东 | 39,283,401.38 | 54,553,799.46 | -27.99 | | 的净利润 | | | | | 归属于上市公司股东 的扣除非经常性损益 | 24,531,062.63 | 40,965,439.45 | -40.12 | | 的净利润 | | | | | 经营活动产生的现金 | 51,476,358.25 | -61,681,653. ...

吉林省中研高分子材料股份有限公司 2024 年度董事会工作报告 各位股东： 2024 年度，吉林省中研高分子材料股份有限公司（以下简称"公司"）董事 会严格按照《中华人民共和国公司法》《中华人民共和国证券法》《吉林省中研高 分子材料股份有限公司章程》（以下简称"公司章程"）及《吉林省中研高分子材 料股份有限公司董事会议事规则》等规定，勤勉尽责地开展董事会各项工作，不 断规范公司法人治理结构，确保董事会科学决策和规范运作，切实维护公司和全 体股东的合法权益，保障了公司的良好运作和可持续发展。现将公司董事会 2024 年度的主要工作情况报告如下： 一、报告期内经营情况 报告期内，公司实现营业收入 27,709.12 万元，同比下降 5.05%；2024 年归 属于上市公司股东的净利润 3,928.34 万元，同比下降 27.99%；2024 年扣除非经 常性损益后的归属于上市公司股东的净利润 2,453.11 万元，同比下降 40.12%； 2024 年末公司总资产 135,448.48 万元，同比增长 8.80%；2024 年末归属于上市 公司股东的净资产 117,215.40 万元，同比增长 1.29%；20 ...

吉林省中研高分子材料股份有限公司 董事会关于独立董事独立性情况的评估报告 吉林省中研高分子材料股份有限公司董事会 2025 年 4 月 25 日 根据证监会《上市公司独立董事管理办法》、《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等要求，吉林省中研高分子材料股份有限公司（以下简称"公司"）董事会据此 对在任独立董事安亚人、苏志勇和周佰成的独立性情况进行评估并出具如下专项 意见： 经核查公司独立董事的任职经历以及签署的相关自查文件，董事会认为公司 独立董事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等规定对独立董事独立性的相关要求。 ...